Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS.

Chitnis T, Singhal T, Zurawski J, Saraceno TJ, Gopalakrishnan N, Cain L, LaBarre B, King D, Bergmark RW, Maxfield AZ, Cicero S, Pan H, Dubey S, Vaquerano S, Hansel C, Healy B, Saxena S, Lokhande H, Baharnoori M, Madill E, Sheth M, Rodin R, Ye J, Clementi N, Clementi WA, Weiner HL.